US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cohen & Steers

75.10

-0.6400-0.84%

Volume:138.58K

Turnover:10.45M

Market Cap:3.83B

PE:24.56

High:75.90

Open:75.49

Low:75.04

Close:75.74

Loading ...

Overview Company News Filings

Cohen & Steers Inc. Declares Quarterly Dividend of $0.62 Per Share

Cohen & Steers, Inc. Declares Quarterly Dividend

THOMSON REUTERS

Press Release: Cohen & Steers, Inc. Declares Quarterly Dividend

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

Cellectar Announces Plan to Explore Strategic Alternatives

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates

Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor

Reviva to Participate in the Citizens Life Sciences Conference

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Serina Therapeutics to Present at JonesResearch Virtual CNS Day

Press Release: Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)

Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study

Sareum Holdings Advances CNS and Oncology Programs with Strategic Updates

New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Argent BioPharma Enters Germany - Europe's Largest Market

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/CNS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CNS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNS\",,,,,undefined,":{"symbol":"CNS","market":"US","secType":"STK","nameCN":"Cohen & Steers","latestPrice":75.1,"timestamp":1749153600000,"preClose":75.74,"halted":0,"volume":138582,"delay":0,"floatShares":27569691,"shares":50979157,"eps":3.05822,"marketStatus":"Pre-Mkt","change":-0.64,"latestTime":"06-06 07:02:34 EDT","open":75.49,"high":75.895,"low":75.04,"amount":10445976.56576,"amplitude":0.011289,"askPrice":75.62,"askSize":25,"bidPrice":30.04,"bidSize":200,"shortable":3,"etf":0,"ttmEps":3.05822,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749216600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1092369600000,"exchange":"NYSE","adjPreClose":75.06,"dividendRate":0.031824,"postHourTrading":{"tag":"盘后","latestPrice":75.1,"preClose":75.1,"latestTime":"16:04 EDT","volume":2829,"amount":212457.9,"timestamp":1749153854525},"volumeRatio":0.8972031595101908,"impliedVol":0.2067,"impliedVolPercentile":0.2169},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CNS\",,,,,undefined,":{"symbol":"CNS","floatShares":27569691,"roa":"14.72%","roe":"30.76%","lyrEps":3.000753,"volumeRatio":0.8972031595101908,"shares":50979157,"dividePrice":2.39,"high":75.895,"amplitude":0.011289,"preClose":75.74,"low":75.04,"week52Low":67.96,"pbRate":"7.54","psRate":"7.23","week52High":110.67,"institutionHeld":0.6131,"latestPrice":75.1,"committee":0.777778,"eps":3.05822,"divideRate":0.031824,"volume":138582,"delay":0,"ttmEps":3.05822,"open":75.49,"prevYearClose":92.34,"prevWeekClose":76.84,"prevMonthClose":76.84,"prevQuarterClose":80.25,"fiveDayClose":77.46,"twentyDayClose":77.68,"sixtyDayClose":80.35},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CNS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532835848","title":"Cohen & Steers Inc. Declares Quarterly Dividend of $0.62 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2532835848","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532835848?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:25","pubTimestamp":1746131154,"startTime":"0","endTime":"0","summary":"Cohen & Steers Inc. has declared a cash dividend for the second quarter of 2025, with the Board of Directors announcing a value of $0.62 per share of common stock.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cohen & Steers Inc. published the original content used to generate this news brief via PR Newswire  on May 01, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nNDL4m2H9S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4135"],"gpt_icon":0},{"id":"2532880438","title":"Cohen & Steers, Inc. Declares Quarterly Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2532880438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532880438?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:18","pubTimestamp":1746130728,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250501:nTUA7NHCKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4135","CNS"],"gpt_icon":0},{"id":"2532880762","title":"Press Release: Cohen & Steers, Inc. Declares Quarterly Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2532880762","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532880762?lang=en_us&edition=fundamental","pubTime":"2025-05-02 04:18","pubTimestamp":1746130680,"startTime":"0","endTime":"0","summary":"NEW YORK, May 1, 2025 /PRNewswire/ -- The Board of Directors of Cohen & Steers, Inc.  declared a cash dividend for the second quarter of 2025 in the amount of $0.62 per share of common stock payable on May 22, 2025 to stockholders of record as of the close of business on May 12, 2025.About Cohen & Steers. Cohen & Steers is a leading global investment manager specializing in real assets and alternative income, including listed and private real estate, preferred securities, infrastructure, resource equities, commodities, as well as multi-strategy solutions. Founded in 1986, the firm is headquartered in New York City, with offices in London, Dublin, Hong Kong, Tokyo and Singapore.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNS","BK4135"],"gpt_icon":0},{"id":"2532204079","title":"Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC","url":"https://stock-news.laohu8.com/highlight/detail?id=2532204079","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532204079?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:30","pubTimestamp":1746099000,"startTime":"0","endTime":"0","summary":"As SVP, Neuroscience, Dr. Bordey will lead Cassava’s ongoing research and development efforts. AUSTIN, Texas, May 01, 2025  -- Cassava Sciences, Inc. , a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system  disorders, today announced that Angélique Bordey, PhD, has joined the Company as Senior Vice President , Neuroscience, while continuing her tenured academic position at Yale School of Medicine on a part time basis.Dr. Bordey is a highly respected, widely published neuroscientist and tenured professor who has dedicated her career to understanding neuronal signaling and unlocking the neurobiology of diseases such as tuberous sclerosis complex. She has been a member of the Departments of Neurosurgery and Cellular and Molecular Physiology at Yale School of Medicine for more than two dec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cassava-appoints-ang-lique-bordey-113000235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4585","BK4547","CNS","BK4007","SAVA","SAVAW","BK4588"],"gpt_icon":0},{"id":"2532737640","title":"Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month","url":"https://stock-news.laohu8.com/highlight/detail?id=2532737640","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532737640?lang=en_us&edition=fundamental","pubTime":"2025-05-01 19:00","pubTimestamp":1746097200,"startTime":"0","endTime":"0","summary":"NEW YORK, May 01, 2025  -- Axsome Therapeutics, Inc. , a biopharmaceutical company leading a new era in the treatment of central nervous system  disorders, today announced it is joining with Mental Health America  and the broader mental health advocacy community in a consolidated effort to raise awareness and promote action during May’s Mental Health Month.On May 1, as part of Mental Health America’s “Light Up Green” initiative, Axsome’s New York City headquarters, the One World Trade Center building, will be lit in green, the color for mental health awareness, and through the building’s Spireworks program.Axsome’s mission is to improve the lives of individuals living with serious CNS conditions that are difficult to treat or have limited treatment options by developing innovative evidence-based treatments that offer meaningful improvements to the standard of care. And, in the spirit of this year’s Mental Health Month theme of “Turning Advocacy into Action,” Axsome is highlighting the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsome-therapeutics-mental-health-america-110000961.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","BK4204","CNS","AXSM","NAMI","BK4007","BK4505","BK4585"],"gpt_icon":0},{"id":"2531031221","title":"Cellectar Announces Plan to Explore Strategic Alternatives","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031221","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031221?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:05","pubTimestamp":1746014700,"startTime":"0","endTime":"0","summary":"“We have initiated a process to explore alternatives available to the company to maximize stockholder value that includes identifying a strategic partner with the resources to develop iopofosine I131. In addition to iopofosine I131, our platform provides exciting opportunities including our alpha- and Auger-emitting radioconjugates, CLR 225 and CLR 125, respectively, in multiple solid tumor indications as well as our small molecule and oligonucleotide conjugates,” said James Caruso, president and chief executive officer of Cellectar.The company has not set a timetable for completion of the strategic evaluation process and does not intend to disclose information on the progress of any such options unless and until it is determined that further disclosure is necessary. No agreement providing for any transaction has been reached and there can be no assurances that any transaction will result from the process of evaluating strategic alternatives. If the process for evaluating strategic alt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cellectar-announces-plan-explore-strategic-120500740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","BK4139","CLRB","BK4135"],"gpt_icon":0},{"id":"2531403574","title":"Anavex Life Sciences to Participate in The Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531403574","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531403574?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:30","pubTimestamp":1746012600,"startTime":"0","endTime":"0","summary":"NEW YORK, April 30, 2025  -- Anavex Life Sciences Corp.  , a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system  disorders, today announced that it will present at The Citizens Life Sciences Conference, taking place in New York, NY, from May 7 – 8, 2025. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 3:30 PM  on Wednesday, May 7th, 2025.Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/anavex-life-sciences-participate-citizens-113000660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4135","BK4561","BK4590","BK4144","ET","BK4581","CNS","BK4139","BK4585","AVXL"],"gpt_icon":0},{"id":"2531794241","title":"Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2531794241","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531794241?lang=en_us&edition=fundamental","pubTime":"2025-04-30 04:05","pubTimestamp":1745957100,"startTime":"0","endTime":"0","summary":"Achieved $13.8 million in ZURZUVAE  collaboration revenue in the first quarter of 2025 , representing a 21% increase from the fourth quarter. Sustained growth in shipments to women with postpartum depression; Greater than 3,000 shipments in first quarter of 2025 . Cash, cash equivalents, and marketable securities of $424 million as of March 31, 2025; Cash runway expected to support operations to mid-2027. CAMBRIDGE, Mass., April 29, 2025----Sage Therapeutics, Inc. , today reported business highlights and financial results for the first quarter ended March 31, 2025.\"We delivered strong growth in revenue and shipments of ZURZUVAE during the first quarter of 2025 through the team’s disciplined execution and unwavering commitment to bringing ZURZUVAE to more women with postpartum depression,\" said Barry Greene, Chief Executive Officer at Sage Therapeutics. \"We remain focused on establishing ZURZUVAE as the standard of care for women with postpartum depression and driving our business strat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sage-therapeutics-announces-first-quarter-200500915.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4211","BK4081","BK4121","PAM","PPD","SAGE","BK4563","BK4139","CNS","BK4530","GABA","BK4561","BK4135"],"gpt_icon":0},{"id":"2531761270","title":"Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor","url":"https://stock-news.laohu8.com/highlight/detail?id=2531761270","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531761270?lang=en_us&edition=fundamental","pubTime":"2025-04-30 01:09","pubTimestamp":1745946540,"startTime":"0","endTime":"0","summary":"\"Zidesamtinib was specifically designed with the goal of addressing the combined medical needs of treating tumors that have developed resistance, treating brain metastases and avoiding off-target adverse events. Structural studies play a critical role in the development and optimization of novel therapeutics, particularly when aiming to solve for multiple, and at times competing, challenges. To date, structural studies for ROS1-positive cancers have been hindered by a lack of ROS1 G2032R crystal structures, despite G2032R being the most commonly occurring ROS1 resistance mutation,\" said first author Anupong Tangpeerachaikul, Ph.D., Director, Biology at Nuvalent. \"With this publication inMolecular Cancer Therapeutics, we are pleased to have shared what is, to our knowledge, the first structure of ROS1 G2032R, or any ROS1 mutation, offering a framework for understanding ROS1 TKI activity against these important drivers of disease progression. This structure further illustrates the intent","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nuvalent-announces-publication-molecular-cancer-170900549.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nuvalent-announces-publication-molecular-cancer-170900549.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4139","BK4135","BK4007","NUVL","BK4539","CNS"],"gpt_icon":0},{"id":"2531603736","title":"Reviva to Participate in the Citizens Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2531603736","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531603736?lang=en_us&edition=fundamental","pubTime":"2025-04-29 20:00","pubTimestamp":1745928000,"startTime":"0","endTime":"0","summary":"CUPERTINO, Calif., April 29, 2025  -- Reviva Pharmaceuticals Holdings, Inc.  , a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system , inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New York, NY.Citizens Life Sciences Conference Format: Corporate Update / Fireside ChatDate: Thursday, May 8, 2025Time: 10:30 a.m. ETLocation: New York, NYWebcast Link: Click Here. About RevivaReviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system , inflammatory and cardiometabolic diseases. Reviva's pipeline currently include","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/reviva-participate-citizens-life-sciences-120000837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","RVPHW","RVPH","CNS","BK4135"],"gpt_icon":0},{"id":"2531314781","title":"Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2531314781","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531314781?lang=en_us&edition=fundamental","pubTime":"2025-04-29 19:02","pubTimestamp":1745924520,"startTime":"0","endTime":"0","summary":"MIAMI, April 29, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven cancer indications, today announced the Company has completed enrollment and initial dosing of three subjects in Cohort 6 with 30 mg capsules of PAS-004.The ongoing Phase 1 clinical trial is a multi-center, open-label, dose escalation 3+3 study design to evaluate the safety, tolerability, pharmacokinetics , pharmacodynamics , and preliminary efficacy of PAS-004 in patients with MAPK pathway driven advanced solid tumors with a documented RAS, NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition .","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-announces-completion-enrollment-110200697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4023","KTTAW","CNS","BK4139","BK4181","IE00B19Z4B17.USD","BK4135","AEIS","BK4007","PD","IE00B66KJ199.SGD","LU1169590202.USD","BK4218","IE00B7SZL793.SGD","LU1169589451.USD","BK4157","IE0031619046.USD","KTTA","PK","LENZ"],"gpt_icon":0},{"id":"2531920241","title":"Serina Therapeutics to Present at JonesResearch Virtual CNS Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2531920241","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531920241?lang=en_us&edition=fundamental","pubTime":"2025-04-29 18:00","pubTimestamp":1745920800,"startTime":"0","endTime":"0","summary":"HUNTSVILLE, AL, April 29, 2025  -- Serina Therapeutics, Inc.  , a clinical-stage biotechnology company developing its proprietary POZ Platformdrug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present at the JonesResearch Hosts: Virtual CNS Day on April 29, 2025, at 12:00 p.m. EDT.Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. Serina’s POZ PlatformTMprovides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates . Serina is headquartered in Huntsville, Alabama on the campus of the HudsonAlpha Institute of Biotechnology.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/serina-therapeutics-present-jonesresearch-virtual-100000150.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","SER","LENZ","BK4135","BK4007","BK4139"],"gpt_icon":0},{"id":"2531260345","title":"Press Release: Cohen & Steers Infrastructure Fund, Inc. (UTF) Notification of Sources of Distribution Under Section 19(a)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531260345","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531260345?lang=en_us&edition=fundamental","pubTime":"2025-04-29 06:04","pubTimestamp":1745877840,"startTime":"0","endTime":"0","summary":"NEW YORK, April 28, 2025 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc.   with information regarding the sources of the distribution to be paid on April 30, 2025 and cumulative distributions paid fiscal year-to-date.In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission. The managed distribution policy seeks to deliver the Fund's long-term total return potential through regular monthly distributions declared at a fixed rate per common share. This policy gives the Fund greater flexibility to realize long-term capital gains throughout the year and to distribute those gains on a regular monthly basis to shareholders. The Board of Directors of the Fund may amend, terminate or suspend the managed distribution policy at any time, which could have an adverse effect on the market price of the Fund's shares.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4135","NAV","CNS","UTF"],"gpt_icon":0},{"id":"2531392260","title":"Sangamo Therapeutics to Present Neurology Pipeline Advances at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531392260","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531392260?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:31","pubTimestamp":1745872260,"startTime":"0","endTime":"0","summary":"One abstract accepted as platform presentation in prestigious Presidential Symposium, demonstrating potent combination of epigenetic regulation and capsid delivery technology in treating prion disease in animal models. \"We are proud to be showcasing our latest pipeline advances at ASGCT, including three platform presentations, reflecting our mission to develop innovative neurology genomic medicines to treat debilitating neurological diseases,\" said Sandy Macrae, Chief Executive Officer of Sangamo Therapeutics. \"We are particularly excited to be presenting, in the prestigious Presidential Symposium, our potent combination of epigenetic regulation and capsid delivery capabilities as an anticipated one-time intravenous treatment for prion disease. It will be an honor to highlight the groundbreaking potential of our work and the dedication of our teams in advancing treatment options for neurology patients in need.\". Additional poster presentations at the ASGCT Annual Meeting will showcase ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/sangamo-therapeutics-present-neurology-pipeline-203100252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","BK4556","AFG","BK4550","BK4588","BK4585","BK4117","MINT","BK4135","BK4139","CNS","SGMO","BK4007","BK4107"],"gpt_icon":0},{"id":"2531341260","title":"Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2531341260","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531341260?lang=en_us&edition=fundamental","pubTime":"2025-04-29 04:30","pubTimestamp":1745872200,"startTime":"0","endTime":"0","summary":"- Oral presentation on tau silencing gene therapy VY1706, which has previously shown up to 73% knockdown of tau mRNA in NHPs in the CNS following a single IV dose of 1.3e13 vg/kg -. - Featured data also include anti-amyloid gene therapy for Alzheimer’s disease, as well as multiple presentations on Voyager’s continued enhancements to its highly BBB penetrant novel capsids -. LEXINGTON, Mass., April 28, 2025  -- Voyager Therapeutics, Inc. , a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced eight oral and poster presentations at the upcoming American Society of Gene & Cell Therapy’s  28th annual meeting taking place in New Orleans, May 13-17, 2025.Cross-species BBB-penetrant IV-delivered AAV gene therapy provides broad and robust CNS tau lowering in tauopathy mouse models and non-human primate . Hechen Bao, Ph.D., Scientist II, Neuroscience. Tuesday, May 13, 2025, 6:00 p.m. – 7:30 p.m. CT. Oral Presentation: Discovery of AAV9-derived ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/voyager-next-generation-cns-capsids-203000971.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","VYGR","BK4135","CNS"],"gpt_icon":0},{"id":"2530056724","title":"Bright Minds Biosciences to Host Virtual R&D Day on May 20, 2025; Program Highlights Include an Overview of Absence Seizures and the BMB-101 Phase 2 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2530056724","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530056724?lang=en_us&edition=fundamental","pubTime":"2025-04-28 20:00","pubTimestamp":1745841600,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, April 28, 2025  -- Bright Minds Biosciences Inc.   , a company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system  disorders, today announced that it will host a virtual R&D Day on Tuesday, May 20, 2025, from 10:00 am – 11:30 am ET.The event will provide an overview of absence seizures and will focus on the unmet need in this group of epilepsy patients. The webcast will include presentations from renowned Key Opinion Leaders  in epilepsy research, as well as an overview of the Company’s BREAKTHROUGH study, an open-label Phase 2 clinical trial evaluating the safety, tolerability, and efficacy of BMB-101 in adult patients with classic Absence Epilepsy and Developmental and Epileptic Encephalopathy . Attendees will have the opportunity to ask questions at the conclusion of the program.Bright Minds is a biotechnology company developing innovative treatments for patient","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bright-minds-biosciences-host-virtual-120000735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","BK4218","BK4139","DRUG","BK4588","HST","BK4135","BK4181","BK4585"],"gpt_icon":0},{"id":"2530122448","title":"Sareum Holdings Advances CNS and Oncology Programs with Strategic Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2530122448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530122448?lang=en_us&edition=fundamental","pubTime":"2025-04-28 14:15","pubTimestamp":1745820918,"startTime":"0","endTime":"0","summary":"The latest update is out from Sareum Holdings ( ($GB:SAR) ). Sareum Holdings has provided an update on its TYK2/JAK1 and SRA737 programs, highlight...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/sareum-holdings-advances-cns-and-oncology-programs-with-strategic-updates?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/sareum-holdings-advances-cns-and-oncology-programs-with-strategic-updates?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4135","CNS"],"gpt_icon":0},{"id":"2530316033","title":"New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2530316033","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530316033?lang=en_us&edition=fundamental","pubTime":"2025-04-26 04:15","pubTimestamp":1745612100,"startTime":"0","endTime":"0","summary":"FRIENDSWOOD, Texas, April 25, 2025  -- Castle Biosciences, Inc. , a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients with cutaneous and uveal melanoma  via poster presentations at the American Association for Cancer Research  Annual Meeting 2025, being held April 25-30 in Chicago.\"At Castle Biosciences, our commitment to advancing care for melanoma patients helps drive our continuous innovation,\" said Rebecca Critchley-Thorne, Ph.D., vice president, research and development, of Castle Biosciences. \"The new data being presented at AACR underscores this commitment and further advances our mission to improve health through innovative tests that can help guide personalized treatment strategies designed to enhance patient outcomes.”Castle will present the following posters at AACR . The corresponding abstracts are available on AACR’s website using the inline links below.Lead Author and Presenter: Merv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/data-aacr-annual-meeting-highlights-201500277.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","DM","CSTL","BK4135","BK4139","BK4546","SLN","BK4196","SSI","CNS"],"gpt_icon":0},{"id":"2529607368","title":"Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2529607368","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529607368?lang=en_us&edition=fundamental","pubTime":"2025-04-24 19:02","pubTimestamp":1745492520,"startTime":"0","endTime":"0","summary":"Poster presentation on Monday, June 2, 2025 from 1:30 – 4:30 PM CDT at the ASCO Annual Meeting. MIAMI, April 24, 2025  -- Pasithea Therapeutics Corp.  , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1  and other MAPK pathway driven indications, today announced the acceptance of an abstract for a poster prenstation at the Annual Meeting of the American Society for Clinical Oncology  taking place May 30 – June 3, 2025, in Chicago, Illinois.The Company will present updated interim clinical data from its onging Phase 1 clinical trial of PAS-004 in patients with MAPK pathway driven advanced solid tumors.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pasithea-therapeutics-present-updated-data-110200343.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1169589451.USD","IE00B66KJ199.SGD","BK4135","BK4157","KTTAW","BK4139","PD","PK","IE0031619046.USD","BK4181","BK4023","LU1169590202.USD","KTTA","BK4218","CNS","LENZ","IE00B19Z4B17.USD","BK4007","AEIS","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2529698743","title":"Argent BioPharma Enters Germany - Europe's Largest Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2529698743","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529698743?lang=en_us&edition=fundamental","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"Strategic Expansion Paired with Over $1M in Annual Cost Savings from Operational Restructuring. PERTH, Australia, April 23, 2025 /PRNewswire/ --Argent BioPharma Ltd.  , a clinical-stage biopharmaceutical company specializing in neuroimmune therapies, is pleased to announce its official entry into the German pharmaceutical market with the receipt of initial purchase orders for CannEpil and CogniCann, following recent regulatory approval. Germany, as the largest healthcare market in Europe, represents a significant commercial milestone and a strategic beachhead for Argent's broader European expansion.These achievements reflect Argent BioPharma's broader transformation strategy—centered on fully proprietary, neuroimmune drug development, in-house innovation, and sustainable global scalability. The Company remains focused on advancing its therapeutic pipeline while deepening market penetration across high-value regions.About Argent BioPharmaArgent BioPharma Ltd.  develops proprietary thera","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance_au","url":"https://finance.yahoo.com/news/argent-biopharma-enters-germany-europes-230000750.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/argent-biopharma-enters-germany-europes-230000750.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["NIM.AU","BK4135","CNS","BK7095","RGT.AU","BK7096","NIM"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CNS\",params:#limit:5,,,undefined,":[{"date":"2025-05-12","symbol":"CNS","amount":0.62,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-12","defaultRemindTime":1747056600000,"name":"科恩-斯蒂尔斯金融","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-22","payableDate":"2025-05-12","currency":"USD","dateTimestamp":1747022400000,"payDate":"2025-05-22"},{"date":"2025-04-16","symbol":"CNS","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":null,"defaultRemindTime":1744833600000,"name":null,"time":"Post Market","dateTimestamp":1744776000000,"actualEps":null},{"date":"2025-03-03","symbol":"CNS","amount":0.62,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-03","defaultRemindTime":1741012200000,"name":"科恩-斯蒂尔斯金融","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-13","payableDate":"2025-03-03","currency":"USD","dateTimestamp":1740978000000,"payDate":"2025-03-13"},{"market":"US","date":"2025-01-22","symbol":"CNS","fiscalQuarterEnding":"2024/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1737522000000,"reportTimeType":"post","actualEps":0.78},{"date":"2024-11-18","symbol":"CNS","amount":0.59,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-18","defaultRemindTime":1731940200000,"name":"科恩-斯蒂尔斯金融","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-02","payableDate":"2024-11-18","currency":"USD","dateTimestamp":1731906000000,"payDate":"2024-12-02"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CNS\",market:\"US\",,,undefined,":[{"executeDate":"2015-09-01","recordDate":"2015-09-03","paymentDate":"2015-09-24","value":0.25,"currency":"USD"},{"executeDate":"2015-11-23","recordDate":"2015-11-25","paymentDate":"2015-12-16","value":0.75,"currency":"USD"},{"executeDate":"2016-03-07","recordDate":"2016-03-09","paymentDate":"2016-03-23","value":0.26,"currency":"USD"},{"executeDate":"2016-05-31","recordDate":"2016-06-02","paymentDate":"2016-06-23","value":0.26,"currency":"USD"},{"executeDate":"2016-08-30","recordDate":"2016-09-01","paymentDate":"2016-09-22","value":0.26,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CNS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0.5,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":2,"updateTime":1729137600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CNS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CNS","date":"2025-06-05","current":24.587277,"percent":0.42916,"low":12.87852,"twenty":18.128761,"median":26.362523,"eighty":33.522419,"high":43.702499,"avg":26.250909,"sd":7.575665,"marketCap":3861161351},"quantilePoints":[{"date":"2020-06-12","current":26.802613,"twenty":17.91219,"median":21.888209,"eighty":25.860348,"marketCap":3287340424},{"date":"2020-06-19","current":27.643845,"twenty":17.91219,"median":21.929604,"eighty":25.901982,"marketCap":3390517630},{"date":"2020-06-26","current":25.143514,"twenty":17.91219,"median":21.929604,"eighty":25.953213,"marketCap":3083852046},{"date":"2020-07-02","current":26.319683,"twenty":17.91219,"median":21.967124,"eighty":25.986175,"marketCap":3228109065},{"date":"2020-07-10","current":26.152215,"twenty":17.91219,"median":22.016567,"eighty":25.992492,"marketCap":3207569158},{"date":"2020-07-17","current":26.362523,"twenty":17.91219,"median":22.08441,"eighty":26.071486,"marketCap":3233363460},{"date":"2020-07-24","current":25.339106,"twenty":17.91219,"median":22.145224,"eighty":26.111636,"marketCap":3036562493},{"date":"2020-07-31","current":23.987847,"twenty":17.91219,"median":22.179183,"eighty":26.111636,"marketCap":2874631600},{"date":"2020-08-07","current":24.132484,"twenty":17.91219,"median":22.253822,"eighty":26.111636,"marketCap":2891964508},{"date":"2020-08-14","current":24.666724,"twenty":17.935145,"median":22.29366,"eighty":26.111636,"marketCap":2955986191},{"date":"2020-08-21","current":24.654763,"twenty":17.935145,"median":22.345044,"eighty":26.111636,"marketCap":2954552870},{"date":"2020-08-28","current":24.499276,"twenty":17.958411,"median":22.424008,"eighty":26.111636,"marketCap":2935919693},{"date":"2020-09-04","current":23.969023,"twenty":18.000138,"median":22.496172,"eighty":26.111636,"marketCap":2872375785},{"date":"2020-09-11","current":23.263348,"twenty":18.099298,"median":22.501958,"eighty":26.111636,"marketCap":2787809831},{"date":"2020-09-18","current":22.832767,"twenty":18.192403,"median":22.546509,"eighty":26.111636,"marketCap":2736210266},{"date":"2020-09-25","current":22.155,"twenty":18.28108,"median":22.546509,"eighty":26.111636,"marketCap":2654988728},{"date":"2020-10-02","current":22.705187,"twenty":18.403976,"median":22.566583,"eighty":26.111636,"marketCap":2720921506},{"date":"2020-10-09","current":23.602231,"twenty":18.52773,"median":22.594828,"eighty":26.111636,"marketCap":2828420600},{"date":"2020-10-16","current":23.598244,"twenty":18.562573,"median":22.670837,"eighty":26.111636,"marketCap":2827942826},{"date":"2020-10-23","current":23.437391,"twenty":18.624451,"median":22.7205,"eighty":26.111636,"marketCap":2759143406},{"date":"2020-10-30","current":22.852978,"twenty":18.788661,"median":22.762059,"eighty":26.111636,"marketCap":2690343986},{"date":"2020-11-06","current":23.997588,"twenty":18.837817,"median":22.78812,"eighty":26.111636,"marketCap":2825092062},{"date":"2020-11-13","current":25.820138,"twenty":18.884452,"median":22.835905,"eighty":26.122473,"marketCap":3039649967},{"date":"2020-11-20","current":28.109489,"twenty":18.914144,"median":22.857139,"eighty":26.15386,"marketCap":3309161456},{"date":"2020-11-27","current":29.432766,"twenty":18.924936,"median":22.889551,"eighty":26.180357,"marketCap":3464942919},{"date":"2020-12-04","current":30.557145,"twenty":18.972497,"median":22.931471,"eighty":26.234833,"marketCap":3597309378},{"date":"2020-12-11","current":30.5815,"twenty":19.026142,"median":22.993772,"eighty":26.256821,"marketCap":3600176521},{"date":"2020-12-18","current":30.191823,"twenty":19.058337,"median":23.028301,"eighty":26.31233,"marketCap":3554302225},{"date":"2020-12-24","current":29.794029,"twenty":19.093721,"median":23.060018,"eighty":26.337042,"marketCap":3507472215},{"date":"2020-12-31","current":30.15935,"twenty":19.103205,"median":23.125625,"eighty":26.362312,"marketCap":3550479367},{"date":"2021-01-08","current":29.091799,"twenty":19.162181,"median":23.160033,"eighty":26.401457,"marketCap":3424802910},{"date":"2021-01-15","current":29.887389,"twenty":19.202231,"median":23.200606,"eighty":26.441488,"marketCap":3518462931},{"date":"2021-01-22","current":29.74126,"twenty":19.221971,"median":23.235659,"eighty":26.487931,"marketCap":3501260070},{"date":"2021-01-29","current":40.869698,"twenty":19.278958,"median":23.263348,"eighty":26.526288,"marketCap":3129964987},{"date":"2021-02-05","current":42.298578,"twenty":19.312251,"median":23.304616,"eighty":26.539566,"marketCap":3239394297},{"date":"2021-02-12","current":43.072294,"twenty":19.369502,"median":23.346381,"eighty":26.568376,"marketCap":3298648596},{"date":"2021-02-19","current":41.312714,"twenty":19.404944,"median":23.412011,"eighty":26.604536,"marketCap":3163892852},{"date":"2021-02-26","current":40.543706,"twenty":19.462875,"median":23.44404,"eighty":26.627953,"marketCap":3104999179},{"date":"2021-03-05","current":41.494638,"twenty":19.519205,"median":23.521823,"eighty":26.663067,"marketCap":3177825348},{"date":"2021-03-12","current":42.773043,"twenty":19.606366,"median":23.562376,"eighty":26.674223,"marketCap":3275730727},{"date":"2021-03-19","current":41.356092,"twenty":19.606366,"median":23.598948,"eighty":26.704024,"marketCap":3167214913},{"date":"2021-03-26","current":40.990833,"twenty":19.607142,"median":23.626615,"eighty":26.73796,"marketCap":3139241947},{"date":"2021-04-01","current":42.307023,"twenty":19.607142,"median":23.674531,"eighty":26.795994,"marketCap":3240041082},{"date":"2021-04-09","current":41.878789,"twenty":19.606366,"median":23.704202,"eighty":26.872012,"marketCap":3207245191},{"date":"2021-04-16","current":42.502248,"twenty":19.606366,"median":23.710206,"eighty":26.913332,"marketCap":3254992149},{"date":"2021-04-23","current":31.693219,"twenty":19.606366,"median":23.710206,"eighty":27.029751,"marketCap":3323477686},{"date":"2021-04-30","current":31.283888,"twenty":19.606366,"median":23.755094,"eighty":27.056161,"marketCap":3280553653},{"date":"2021-05-07","current":32.560979,"twenty":19.606366,"median":23.782134,"eighty":27.213028,"marketCap":3414474551},{"date":"2021-05-14","current":33.61905,"twenty":19.606366,"median":23.8007,"eighty":27.25402,"marketCap":3525428090},{"date":"2021-05-21","current":33.200422,"twenty":19.606366,"median":23.839623,"eighty":27.262589,"marketCap":3481529081},{"date":"2021-05-28","current":33.642052,"twenty":19.606366,"median":23.883463,"eighty":27.340067,"marketCap":3527840123},{"date":"2021-06-04","current":34.226291,"twenty":19.606366,"median":23.921975,"eighty":27.431277,"marketCap":3589105773},{"date":"2021-06-11","current":34.424104,"twenty":19.606366,"median":23.95944,"eighty":27.60508,"marketCap":3609849261},{"date":"2021-06-18","current":35.633985,"twenty":19.606366,"median":23.983072,"eighty":27.65774,"marketCap":3736722220},{"date":"2021-06-25","current":37.754727,"twenty":19.606366,"median":24.001439,"eighty":27.731371,"marketCap":3959111704},{"date":"2021-07-02","current":37.317698,"twenty":19.606366,"median":24.019996,"eighty":27.803594,"marketCap":3913283069},{"date":"2021-07-09","current":36.871468,"twenty":19.606366,"median":24.065621,"eighty":27.878924,"marketCap":3866489620},{"date":"2021-07-16","current":36.443639,"twenty":19.606366,"median":24.065621,"eighty":27.954254,"marketCap":3821625798},{"date":"2021-07-23","current":32.23161,"twenty":19.606366,"median":24.065621,"eighty":28.3446,"marketCap":3962006144},{"date":"2021-07-30","current":32.655452,"twenty":19.606366,"median":24.065621,"eighty":28.597983,"marketCap":4014106067},{"date":"2021-08-06","current":34.262979,"twenty":19.606366,"median":24.065621,"eighty":28.779046,"marketCap":4211708107},{"date":"2021-08-13","current":34.608395,"twenty":19.606366,"median":24.065621,"eighty":28.919847,"marketCap":4254167761},{"date":"2021-08-20","current":34.376809,"twenty":19.606366,"median":24.065621,"eighty":29.018684,"marketCap":4225700493},{"date":"2021-08-27","current":34.690824,"twenty":19.606366,"median":24.065621,"eighty":29.125292,"marketCap":4264300178},{"date":"2021-09-03","current":34.518116,"twenty":19.606366,"median":24.065621,"eighty":29.237927,"marketCap":4243070351},{"date":"2021-09-10","current":34.015692,"twenty":19.606366,"median":24.065621,"eighty":29.325721,"marketCap":4181310855},{"date":"2021-09-17","current":34.235502,"twenty":19.606366,"median":24.065621,"eighty":29.428707,"marketCap":4208330635},{"date":"2021-09-24","current":33.650649,"twenty":19.606366,"median":24.065621,"eighty":29.513948,"marketCap":4136438722},{"date":"2021-10-01","current":33.485791,"twenty":19.606366,"median":24.065621,"eighty":29.715133,"marketCap":4116173887},{"date":"2021-10-08","current":33.897936,"twenty":19.607142,"median":24.072911,"eighty":29.833679,"marketCap":4166835974},{"date":"2021-10-15","current":34.282604,"twenty":19.607142,"median":24.072911,"eighty":29.886999,"marketCap":4214120588},{"date":"2021-10-22","current":31.39397,"twenty":19.607142,"median":24.120524,"eighty":29.97263,"marketCap":4473703468},{"date":"2021-10-29","current":32.128708,"twenty":19.607919,"median":24.159112,"eighty":30.0979,"marketCap":4578405113},{"date":"2021-11-05","current":34.01649,"twenty":19.607919,"median":24.231662,"eighty":30.206436,"marketCap":4847417859},{"date":"2021-11-12","current":33.779441,"twenty":19.607919,"median":24.272267,"eighty":30.2663,"marketCap":4813637944},{"date":"2021-11-19","current":33.335822,"twenty":19.607919,"median":24.34227,"eighty":30.314228,"marketCap":4750421245},{"date":"2021-11-26","current":31.585048,"twenty":19.607919,"median":24.388858,"eighty":30.347179,"marketCap":4500932441},{"date":"2021-12-03","current":30.152596,"twenty":19.607919,"median":24.435486,"eighty":30.418709,"marketCap":4296805238},{"date":"2021-12-10","current":30.687649,"twenty":19.607919,"median":24.495428,"eighty":30.555834,"marketCap":4373051333},{"date":"2021-12-17","current":30.917925,"twenty":19.607919,"median":24.535811,"eighty":30.628753,"marketCap":4405866108},{"date":"2021-12-23","current":30.464146,"twenty":19.607919,"median":24.549254,"eighty":30.66128,"marketCap":4341201699},{"date":"2021-12-31","current":31.32768,"twenty":19.607919,"median":24.669496,"eighty":30.712708,"marketCap":4464257105},{"date":"2022-01-07","current":30.782468,"twenty":19.609472,"median":24.728839,"eighty":30.771039,"marketCap":4386563299},{"date":"2022-01-14","current":29.597225,"twenty":19.609472,"median":24.776362,"eighty":30.771039,"marketCap":4217663722},{"date":"2022-01-21","current":28.411981,"twenty":19.609472,"median":24.864401,"eighty":30.771039,"marketCap":4048764145},{"date":"2022-01-28","current":18.641168,"twenty":19.590769,"median":24.917596,"eighty":30.771039,"marketCap":3940668416},{"date":"2022-02-04","current":18.285055,"twenty":19.499836,"median":24.917596,"eighty":30.771039,"marketCap":3865387462},{"date":"2022-02-11","current":18.433435,"twenty":19.415099,"median":24.917596,"eighty":30.771039,"marketCap":3896754526},{"date":"2022-02-18","current":18.221137,"twenty":19.383827,"median":24.917596,"eighty":30.771039,"marketCap":3851875496},{"date":"2022-02-25","current":18.59767,"twenty":19.32955,"median":24.882576,"eighty":30.771039,"marketCap":3931473126},{"date":"2022-03-04","current":17.962167,"twenty":19.282693,"median":24.776362,"eighty":30.771039,"marketCap":3797130353},{"date":"2022-03-11","current":17.870066,"twenty":19.226995,"median":24.690202,"eighty":30.771039,"marketCap":3777660385},{"date":"2022-03-18","current":19.069692,"twenty":19.199701,"median":24.590174,"eighty":30.771039,"marketCap":4031256708},{"date":"2022-03-25","current":19.266364,"twenty":19.165812,"median":24.531824,"eighty":30.771039,"marketCap":4072832201},{"date":"2022-04-01","current":20.194336,"twenty":19.165812,"median":24.414953,"eighty":30.771039,"marketCap":4269001841},{"date":"2022-04-08","current":19.798278,"twenty":19.165812,"median":24.34446,"eighty":30.771039,"marketCap":4185276833},{"date":"2022-04-14","current":19.006163,"twenty":19.164835,"median":24.272267,"eighty":30.771039,"marketCap":4017826818},{"date":"2022-04-22","current":19.515002,"twenty":19.160428,"median":24.159112,"eighty":30.771039,"marketCap":3992027833},{"date":"2022-04-29","current":18.48702,"twenty":19.120759,"median":24.109263,"eighty":30.771039,"marketCap":3781741767},{"date":"2022-05-06","current":18.140576,"twenty":19.097352,"median":24.008501,"eighty":30.771039,"marketCap":3710872529},{"date":"2022-05-13","current":17.343267,"twenty":19.068709,"median":23.966477,"eighty":30.771039,"marketCap":3547773304},{"date":"2022-05-20","current":17.248065,"twenty":19.045263,"median":23.843035,"eighty":30.771039,"marketCap":3528298769},{"date":"2022-05-27","current":18.354779,"twenty":19.014348,"median":23.76195,"eighty":30.771039,"marketCap":3754690232},{"date":"2022-06-03","current":17.897813,"twenty":18.977944,"median":23.679147,"eighty":30.771039,"marketCap":3661212467},{"date":"2022-06-10","current":16.634018,"twenty":18.947577,"median":23.585518,"eighty":30.771039,"marketCap":3402688023},{"date":"2022-06-17","current":15.608226,"twenty":18.914815,"median":23.455654,"eighty":30.689004,"marketCap":3192849914},{"date":"2022-06-24","current":16.260354,"twenty":18.900025,"median":23.315177,"eighty":30.690358,"marketCap":3326250475},{"date":"2022-07-01","current":15.477324,"twenty":18.870215,"median":23.246645,"eighty":30.690358,"marketCap":3166072430},{"date":"2022-07-08","current":15.736747,"twenty":18.832714,"median":23.109571,"eighty":30.614098,"marketCap":3219140536},{"date":"2022-07-15","current":16.162773,"twenty":18.79571,"median":22.956359,"eighty":30.520819,"marketCap":3306289077},{"date":"2022-07-22","current":16.110583,"twenty":18.706811,"median":22.835905,"eighty":30.406577,"marketCap":3382239761},{"date":"2022-07-29","current":17.089231,"twenty":18.655675,"median":22.723109,"eighty":30.285785,"marketCap":3587696099},{"date":"2022-08-05","current":17.336827,"twenty":18.60341,"median":22.666493,"eighty":30.247635,"marketCap":3639676038},{"date":"2022-08-12","current":18.014155,"twenty":18.576102,"median":22.585581,"eighty":30.247635,"marketCap":3781873710},{"date":"2022-08-19","current":17.726522,"twenty":18.553033,"median":22.523144,"eighty":30.247635,"marketCap":3721488397},{"date":"2022-08-26","current":17.097906,"twenty":18.483674,"median":22.467927,"eighty":30.247635,"marketCap":3589517270},{"date":"2022-09-02","current":16.432175,"twenty":18.396609,"median":22.353732,"eighty":30.247635,"marketCap":3449754489},{"date":"2022-09-09","current":17.31595,"twenty":18.356371,"median":22.298527,"eighty":30.247635,"marketCap":3635293233},{"date":"2022-09-16","current":16.842748,"twenty":18.283229,"median":22.249478,"eighty":30.247635,"marketCap":3535949654},{"date":"2022-09-23","current":15.91722,"twenty":18.21193,"median":22.179183,"eighty":30.247635,"marketCap":3341645300},{"date":"2022-09-30","current":14.527769,"twenty":18.176655,"median":22.123505,"eighty":30.247635,"marketCap":3049945280},{"date":"2022-10-07","current":14.019773,"twenty":18.104175,"median":22.045314,"eighty":30.247635,"marketCap":2943297026},{"date":"2022-10-14","current":12.87852,"twenty":18.032153,"median":21.992474,"eighty":30.247635,"marketCap":2703703688},{"date":"2022-10-21","current":13.875906,"twenty":17.988291,"median":21.929604,"eighty":30.247635,"marketCap":2817169639},{"date":"2022-10-28","current":14.518731,"twenty":17.957216,"median":21.836807,"eighty":30.247635,"marketCap":2947679831},{"date":"2022-11-04","current":14.228587,"twenty":17.927938,"median":21.723866,"eighty":30.232415,"marketCap":2888773025},{"date":"2022-11-11","current":16.001462,"twenty":17.901888,"median":21.670268,"eighty":30.232415,"marketCap":3248712878},{"date":"2022-11-18","current":15.814339,"twenty":17.857353,"median":21.62555,"eighty":30.232415,"marketCap":3210721932},{"date":"2022-11-25","current":15.672797,"twenty":17.824307,"median":21.559545,"eighty":30.232415,"marketCap":3181985192},{"date":"2022-12-02","current":16.212576,"twenty":17.737907,"median":21.517024,"eighty":30.232415,"marketCap":3291574457},{"date":"2022-12-09","current":16.03025,"twenty":17.634502,"median":21.398073,"eighty":30.232415,"marketCap":3254557638},{"date":"2022-12-16","current":15.432895,"twenty":17.536399,"median":21.363322,"eighty":30.232415,"marketCap":3133278852},{"date":"2022-12-23","current":15.157007,"twenty":17.453772,"median":21.291372,"eighty":30.232415,"marketCap":3077266561},{"date":"2022-12-30","current":15.488072,"twenty":17.435795,"median":21.271518,"eighty":30.232415,"marketCap":3144481310},{"date":"2023-01-06","current":16.500458,"twenty":17.354712,"median":21.218395,"eighty":30.232415,"marketCap":3350022065},{"date":"2023-01-13","current":17.735954,"twenty":17.299707,"median":21.152857,"eighty":30.232415,"marketCap":3600859716},{"date":"2023-01-20","current":17.532037,"twenty":17.272433,"median":21.104444,"eighty":30.232415,"marketCap":3559459327},{"date":"2023-01-27","current":20.240915,"twenty":17.272433,"median":21.102629,"eighty":30.232415,"marketCap":3462046647},{"date":"2023-02-03","current":21.659032,"twenty":17.272433,"median":21.116232,"eighty":30.232415,"marketCap":3704604220},{"date":"2023-02-10","current":21.055336,"twenty":17.272433,"median":21.15785,"eighty":30.232415,"marketCap":3601346779},{"date":"2023-02-17","current":21.129374,"twenty":17.272433,"median":21.159455,"eighty":30.232415,"marketCap":3614010428},{"date":"2023-02-24","current":20.698656,"twenty":17.272433,"median":21.159455,"eighty":30.232415,"marketCap":3540339494},{"date":"2023-03-03","current":20.580952,"twenty":17.272433,"median":21.159455,"eighty":30.232415,"marketCap":3520207189},{"date":"2023-03-10","current":18.634532,"twenty":17.272433,"median":21.15785,"eighty":30.232415,"marketCap":3187287608},{"date":"2023-03-17","current":18.169458,"twenty":17.272433,"median":21.116232,"eighty":30.232415,"marketCap":3107740452},{"date":"2023-03-24","current":17.469835,"twenty":17.272433,"median":21.115136,"eighty":30.232415,"marketCap":2988075455},{"date":"2023-03-31","current":18.362705,"twenty":17.273887,"median":21.10979,"eighty":30.224296,"marketCap":3140793856},{"date":"2023-04-06","current":17.72248,"twenty":17.272433,"median":21.115136,"eighty":30.232415,"marketCap":3031288379},{"date":"2023-04-14","current":17.659318,"twenty":17.270978,"median":21.115684,"eighty":30.240533,"marketCap":3020485148},{"date":"2023-04-20","current":18.415569,"twenty":17.270978,"median":21.115684,"eighty":30.240533,"marketCap":3026377819},{"date":"2023-04-28","current":17.701417,"twenty":17.269524,"median":21.116232,"eighty":30.248652,"marketCap":2909015447},{"date":"2023-05-05","current":16.207374,"twenty":17.258712,"median":21.116232,"eighty":30.248652,"marketCap":2663487472},{"date":"2023-05-12","current":16.342745,"twenty":17.216458,"median":21.122803,"eighty":30.25677,"marketCap":2685734018},{"date":"2023-05-19","current":16.937516,"twenty":17.1325,"median":21.129374,"eighty":30.263026,"marketCap":2783477447},{"date":"2023-05-26","current":16.037888,"twenty":17.093405,"median":21.143612,"eighty":30.269283,"marketCap":2635634371},{"date":"2023-06-01","current":16.262047,"twenty":17.038241,"median":21.15785,"eighty":30.275539,"marketCap":2672472347},{"date":"2023-06-09","current":18.405015,"twenty":17.00976,"median":21.159455,"eighty":30.288052,"marketCap":3024643395},{"date":"2023-06-16","current":18.36915,"twenty":17.00976,"median":21.159455,"eighty":30.288052,"marketCap":3018749319},{"date":"2023-06-23","current":17.173631,"twenty":16.999409,"median":21.167314,"eighty":30.322625,"marketCap":2822280115},{"date":"2023-06-30","current":17.421701,"twenty":16.956799,"median":21.19089,"eighty":30.357198,"marketCap":2863047475},{"date":"2023-07-07","current":17.176619,"twenty":16.955322,"median":21.194819,"eighty":30.374484,"marketCap":2822771288},{"date":"2023-07-14","current":19.140259,"twenty":16.955322,"median":21.194819,"eighty":30.374484,"marketCap":3145471956},{"date":"2023-07-21","current":22.272461,"twenty":16.9482,"median":21.240006,"eighty":30.381903,"marketCap":3210797966},{"date":"2023-07-28","current":22.401932,"twenty":16.944638,"median":21.281264,"eighty":30.385612,"marketCap":3229462540},{"date":"2023-08-04","current":21.798869,"twenty":16.944638,"median":21.362879,"eighty":30.385612,"marketCap":3142524917},{"date":"2023-08-11","current":22.605317,"twenty":16.944638,"median":21.393729,"eighty":30.385612,"marketCap":3258782486},{"date":"2023-08-18","current":21.616995,"twenty":16.944638,"median":21.462546,"eighty":30.385612,"marketCap":3116305941},{"date":"2023-08-25","current":21.323906,"twenty":16.944638,"median":21.480607,"eighty":30.385612,"marketCap":3074054276},{"date":"2023-09-01","current":22.213396,"twenty":16.941077,"median":21.556303,"eighty":30.389322,"marketCap":3202283166},{"date":"2023-09-08","current":21.569282,"twenty":16.941077,"median":21.60996,"eighty":30.389322,"marketCap":3109427763},{"date":"2023-09-15","current":21.882819,"twenty":16.941077,"median":21.616127,"eighty":30.389322,"marketCap":3154627219},{"date":"2023-09-22","current":21.061489,"twenty":16.941077,"median":21.621272,"eighty":30.389322,"marketCap":3036224297},{"date":"2023-09-29","current":21.156914,"twenty":16.941077,"median":21.621272,"eighty":30.389322,"marketCap":3049980653},{"date":"2023-10-05","current":20.373072,"twenty":16.941077,"median":21.621272,"eighty":30.389322,"marketCap":2936982014},{"date":"2023-10-13","current":19.302957,"twenty":16.962706,"median":21.62555,"eighty":30.393031,"marketCap":2782714307},{"date":"2023-10-20","current":19.766808,"twenty":17.094797,"median":21.635278,"eighty":30.394386,"marketCap":2603881679},{"date":"2023-10-27","current":19.173804,"twenty":17.14802,"median":21.654483,"eighty":30.398449,"marketCap":2525765228},{"date":"2023-11-03","current":20.624613,"twenty":17.21745,"median":21.654483,"eighty":30.398449,"marketCap":2716880317},{"date":"2023-11-10","current":19.788994,"twenty":17.261187,"median":21.654483,"eighty":30.398449,"marketCap":2606804215},{"date":"2023-11-17","current":21.859285,"twenty":17.306392,"median":21.660629,"eighty":30.398449,"marketCap":2879523600},{"date":"2023-11-24","current":21.113234,"twenty":17.347082,"median":21.667395,"eighty":30.398449,"marketCap":2781246344},{"date":"2023-12-01","current":21.818252,"twenty":17.382449,"median":21.672805,"eighty":30.398449,"marketCap":2874118351},{"date":"2023-12-08","current":23.530438,"twenty":17.431804,"median":21.701465,"eighty":30.398449,"marketCap":3099664654},{"date":"2023-12-15","current":27.555382,"twenty":17.450036,"median":21.745585,"eighty":30.398449,"marketCap":3629870450},{"date":"2023-12-22","current":27.365139,"twenty":17.496342,"median":21.810744,"eighty":30.398449,"marketCap":3604809750},{"date":"2023-12-29","current":28.827398,"twenty":17.527254,"median":21.852697,"eighty":30.399804,"marketCap":3797433171},{"date":"2024-01-05","current":26.820522,"twenty":17.571979,"median":21.883893,"eighty":30.40319,"marketCap":3533067353},{"date":"2024-01-12","current":25.46644,"twenty":17.607846,"median":21.929604,"eighty":30.40319,"marketCap":3354694133},{"date":"2024-01-19","current":24.690547,"twenty":17.644846,"median":21.986315,"eighty":30.406577,"marketCap":3252485787},{"date":"2024-01-26","current":26.760864,"twenty":17.711966,"median":22.045314,"eighty":30.40319,"marketCap":3453462775},{"date":"2024-02-02","current":27.042638,"twenty":17.738956,"median":22.116155,"eighty":30.40319,"marketCap":3489825360},{"date":"2024-02-09","current":26.34582,"twenty":17.7688,"median":22.15546,"eighty":30.40319,"marketCap":3399901671},{"date":"2024-02-16","current":27.141639,"twenty":17.80097,"median":22.213396,"eighty":30.40319,"marketCap":3502601403},{"date":"2024-02-23","current":27.30918,"twenty":17.835673,"median":22.249478,"eighty":30.40319,"marketCap":3524222400},{"date":"2024-03-01","current":28.224884,"twenty":17.840133,"median":22.284274,"eighty":30.399804,"marketCap":3642393114},{"date":"2024-03-08","current":29.072974,"twenty":17.854544,"median":22.345044,"eighty":30.399804,"marketCap":3751838236},{"date":"2024-03-15","current":26.943156,"twenty":17.854544,"median":22.410631,"eighty":30.399804,"marketCap":3476987362},{"date":"2024-03-22","current":29.203449,"twenty":17.862113,"median":22.484099,"eighty":30.399804,"marketCap":3768675948},{"date":"2024-03-28","current":29.116605,"twenty":17.870066,"median":22.523144,"eighty":30.399804,"marketCap":3757468730},{"date":"2024-04-05","current":28.065076,"twenty":17.868475,"median":22.583959,"eighty":30.40319,"marketCap":3621769977},{"date":"2024-04-12","current":27.869353,"twenty":17.868475,"median":22.609066,"eighty":30.40319,"marketCap":3596512181},{"date":"2024-04-19","current":25.6312,"twenty":17.868475,"median":22.695824,"eighty":30.40319,"marketCap":3274103832},{"date":"2024-04-26","current":27.635851,"twenty":17.870066,"median":22.753371,"eighty":30.399804,"marketCap":3530175929},{"date":"2024-05-03","current":27.556733,"twenty":17.870066,"median":22.836196,"eighty":30.399804,"marketCap":3520069499},{"date":"2024-05-10","current":29.163628,"twenty":17.870066,"median":22.943915,"eighty":30.399804,"marketCap":3725332736},{"date":"2024-05-17","current":29.183411,"twenty":17.870066,"median":23.090775,"eighty":30.399804,"marketCap":3727859756},{"date":"2024-05-24","current":28.221973,"twenty":17.870066,"median":23.209747,"eighty":30.399804,"marketCap":3605046589},{"date":"2024-05-31","current":27.054795,"twenty":17.870066,"median":23.285328,"eighty":30.399804,"marketCap":3455952415},{"date":"2024-06-07","current":27.822363,"twenty":17.870066,"median":23.445508,"eighty":30.399804,"marketCap":3554000787},{"date":"2024-06-14","current":28.154712,"twenty":17.868475,"median":23.529127,"eighty":30.40319,"marketCap":3596454721},{"date":"2024-06-21","current":28.269451,"twenty":17.866885,"median":23.600941,"eighty":30.406577,"marketCap":3611111437},{"date":"2024-06-28","current":28.00832,"twenty":17.862113,"median":23.655779,"eighty":30.416736,"marketCap":3577754774},{"date":"2024-07-05","current":28.550365,"twenty":17.862113,"median":23.741772,"eighty":30.416736,"marketCap":3646995119},{"date":"2024-07-12","current":29.808544,"twenty":17.862113,"median":23.829483,"eighty":30.416736,"marketCap":3807713585},{"date":"2024-07-15","current":30.034066,"twenty":17.862113,"median":23.84751,"eighty":30.416736,"marketCap":3836521612},{"date":"2024-08-02","current":33.347515,"twenty":17.848785,"median":23.979228,"eighty":30.525101,"marketCap":4259544743},{"date":"2024-08-09","current":32.935122,"twenty":17.848785,"median":24.052267,"eighty":30.630396,"marketCap":4206869033},{"date":"2024-08-16","current":33.287348,"twenty":17.848785,"median":24.123689,"eighty":30.714063,"marketCap":4251859581},{"date":"2024-08-23","current":33.750387,"twenty":17.848785,"median":24.183737,"eighty":30.826419,"marketCap":4311004459},{"date":"2024-08-30","current":34.755617,"twenty":17.848785,"median":24.299974,"eighty":30.970882,"marketCap":4439404451},{"date":"2024-09-06","current":34.79915,"twenty":17.848785,"median":24.36742,"eighty":31.120432,"marketCap":4444965081},{"date":"2024-09-13","current":35.404663,"twenty":17.848785,"median":24.435486,"eighty":31.286647,"marketCap":4522308383},{"date":"2024-09-20","current":37.834627,"twenty":17.848785,"median":24.535811,"eighty":31.405188,"marketCap":4832692616},{"date":"2024-09-27","current":37.620917,"twenty":17.848785,"median":24.628464,"eighty":31.548301,"marketCap":4805394980},{"date":"2024-10-04","current":36.576111,"twenty":17.848785,"median":24.693686,"eighty":31.671335,"marketCap":4671939870},{"date":"2024-10-11","current":36.342613,"twenty":17.848785,"median":24.776362,"eighty":31.921404,"marketCap":4642114675},{"date":"2024-10-18","current":39.372812,"twenty":17.848785,"median":24.882576,"eighty":32.212468,"marketCap":5325566602},{"date":"2024-10-25","current":37.545256,"twenty":17.848785,"median":25.007411,"eighty":32.383174,"marketCap":5078371341},{"date":"2024-10-31","current":37.732123,"twenty":17.848785,"median":25.038793,"eighty":32.531573,"marketCap":5103646930},{"date":"2024-11-08","current":38.195552,"twenty":17.848309,"median":25.036169,"eighty":32.647241,"marketCap":5166330391},{"date":"2024-11-15","current":37.647327,"twenty":17.848309,"median":25.05345,"eighty":32.844946,"marketCap":5092177385},{"date":"2024-11-22","current":38.12203,"twenty":17.848309,"median":25.05345,"eighty":32.996976,"marketCap":5156385738},{"date":"2024-11-29","current":39.120028,"twenty":17.848309,"median":25.05345,"eighty":33.070314,"marketCap":5291374952},{"date":"2024-12-06","current":37.834218,"twenty":17.848309,"median":25.05345,"eighty":33.177608,"marketCap":5117456264},{"date":"2024-12-13","current":37.6249,"twenty":17.848309,"median":25.05345,"eighty":33.254869,"marketCap":5089143920},{"date":"2024-12-20","current":33.890817,"twenty":17.848309,"median":25.143514,"eighty":33.332395,"marketCap":4584071917},{"date":"2024-12-27","current":35.344829,"twenty":17.848309,"median":25.20584,"eighty":33.433016,"marketCap":4780741596},{"date":"2025-01-03","current":34.152464,"twenty":17.848309,"median":25.316828,"eighty":33.484887,"marketCap":4619462348},{"date":"2025-01-10","current":33.449754,"twenty":17.847833,"median":25.412351,"eighty":33.512931,"marketCap":4524413763},{"date":"2025-01-17","current":32.918984,"twenty":17.847833,"median":25.627156,"eighty":33.512931,"marketCap":4452621747},{"date":"2025-01-24","current":29.843666,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4514302211},{"date":"2025-01-31","current":29.689919,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4491045643},{"date":"2025-02-07","current":29.850351,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4515313366},{"date":"2025-02-14","current":28.209267,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4267074775},{"date":"2025-02-21","current":28.924526,"twenty":17.847833,"median":25.682916,"eighty":33.512931,"marketCap":4375268377},{"date":"2025-02-28","current":29.116429,"twenty":17.847833,"median":25.724336,"eighty":33.512931,"marketCap":4404296702},{"date":"2025-03-07","current":28.988386,"twenty":17.846293,"median":25.852331,"eighty":33.522419,"marketCap":4384928194},{"date":"2025-03-14","current":25.446971,"twenty":17.849737,"median":25.966294,"eighty":33.522419,"marketCap":3849236048},{"date":"2025-03-21","current":26.589254,"twenty":17.892782,"median":26.105931,"eighty":33.522419,"marketCap":4022023524},{"date":"2025-03-28","current":26.946428,"twenty":17.939383,"median":26.181536,"eighty":33.522419,"marketCap":4076051467},{"date":"2025-04-04","current":25.986102,"twenty":17.978554,"median":26.303934,"eighty":33.522419,"marketCap":3930787659},{"date":"2025-04-11","current":24.851655,"twenty":18.014155,"median":26.294159,"eighty":33.512931,"marketCap":3759185663},{"date":"2025-04-17","current":23.983353,"twenty":18.072738,"median":26.294159,"eighty":33.512931,"marketCap":3766321745},{"date":"2025-04-25","current":24.944115,"twenty":18.128761,"median":26.303934,"eighty":33.522419,"marketCap":3917198891},{"date":"2025-05-02","current":24.905165,"twenty":18.128761,"median":26.303934,"eighty":33.522419,"marketCap":3911082250},{"date":"2025-05-09","current":25.957204,"twenty":18.128761,"median":26.303934,"eighty":33.522419,"marketCap":4076293393},{"date":"2025-05-16","current":27.109631,"twenty":18.128761,"median":26.362523,"eighty":33.522419,"marketCap":4257269401},{"date":"2025-05-23","current":24.694404,"twenty":18.128761,"median":26.401469,"eighty":33.522419,"marketCap":3877984472},{"date":"2025-05-30","current":25.145636,"twenty":18.128761,"median":26.401469,"eighty":33.522419,"marketCap":3948845501},{"date":"2025-06-05","current":24.587277,"twenty":18.128761,"median":26.362523,"eighty":33.522419,"marketCap":3861161351}],"updateTime":1749207754268}}}